Cyntellect releases new cell cytometry system

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, today unveiled its Celigo™ adherent cell cytometry system, the Company’s new platform for non-invasive in situ live cell imaging. The Celigo Cytometer provides unsurpassed speed, flexibility and precision of cellular analysis across a wide range of applications, including cell health assays, cell culture maintenance, toxicity assays and assays for detecting the highest antibody-secreting cells within a population.

The Celigo Cytometer has both brightfield and multi-color fluorescence modules and easy-to-use analysis software that provide extremely detailed cellular and sub-cellular data on each individual cell in the microplate well, whether adherent or non-adherent. The system offers a diverse range of real-time and endpoint assays, and its small footprint conserves premium research space. The Celigo Cytometer can analyze cells non-destructively, therefore reducing the risk of cell damage and contamination. The system is capable of label-free analysis of live cells and fluorescence cellular analysis.

The Celigo Cytometer will be demonstrated for the first time at the Live Cell Imaging 2009 Annual Meeting in Boston from September 21 to 23. The system will be introduced at a presentation by Dr. Fred Koller, President and CEO of Cyntellect on September 22 at 11:00 a.m. EST. Dr. Koller stated, “We are delighted to announce the commercial availability of the Celigo Cytometer. This product will be of great benefit to researchers using cellular analysis in many different areas, including drug discovery, cancer biology, immunology and biopharmaceutical protein production.”

The Celigo Cytometer is the newest addition to Cyntellect’s line of automated microplate-based cytometry systems, which also includes the LEAP™ Cellular Purification and Processing Workstation. Both systems analyze cells with great precision and simplicity in their natural state, allowing cells to maintain their proper physiologic behavior. Cyntellect has collaborated with top academic research institutions and numerous key opinion leaders in life sciences to validate, refine and enhance both the LEAP and Celigo products.

Source:

Cyntellect, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
MET amplification identified as a potentially actionable driver for non-small cell lung cancer